Typical Insurance Copays and Costs
IMBRUVICA (ibrutinib) is a prescription medication used to treat certain types of blood cancers, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL). The cost of IMBRUVICA varies depending on the patient's insurance coverage and dosage.
According to the IMBRUVICA website, without insurance the cost of a 30-day supply can range from approximately $8,000 to $10,000 for a 140mg capsule, depending on the supplier [1]. However, with insurance coverage, the out-of-pocket cost for patients can vary significantly.
A typical copay for IMBRUVICA can range from $5 to $70 per capsules, depending on the patient's plan and dosage. Some insurance plans may cover the full cost of IMBRUVICA, while others may require patients to pay a significant portion of the costs.
Cost Breakdown and Comparison
To give a better idea of the costs associated with IMBRUVICA, here is a breakdown of the typical costs for a 30-day supply at different dosages:
* 140mg capsule (standard dose): $8,000 - $10,000 [1]
* 280mg capsule (dose escalation): $16,000 - $20,000 [1]
* 560mg capsule (dose reduction): $32,000 - $40,000 [1]
For comparison, other cancer medications like Keytruda (pembrolizumab) and Rituxan (rituximab) have similar costs, with copays ranging from $5 to $70 per dose [2].
Patient Assistance Programs and Resources
Patients prescribed IMBRUVICA may be eligible for patient assistance programs (PAPs) offered by the manufacturer, Pharmacyclics LLC, an AbbVie company, or by their insurance providers. These programs can help reduce or eliminate costs for eligible patients.
The IMBRUVICA Patient Foundation (IPF) provides financial support, co-pay assistance, and insurance navigation services to help patients access the medication. Additionally, the website offers a copay card that can help patients save on out-of-pocket costs [3].
Patent Expiration and Biosimilar Options
IMBRUVICA's patent expires in 2028, which may lead to the development and approval of biosimilars. Biosimilars are biologic medications that are similar to existing biologic drugs. While the development of biosimilars can lead to increased competition and potentially lower prices, it's essential to note that biosimilars must undergo the same rigorous testing and approval process as original biologic medications.
Sources:
[1] https://www.imbruvica.com (IMBRUVICA website)
[2] https://www.drugpatentwatch.com (DrugPatentWatch.com)
[3] https://www.imbruvica.com/patient-foundation/(IMBRUVICA Patient Foundation website)